Re-analysis of DYSIS-China cross-sectional survey according to " Chinese guidelines for the prevention and treatment of dyslipidemia in adults (2016 revision)"

Objective To investigate the status and characteristics of blood lipids in Chinese dyslipidemia patients treated with lipid-lowering therapy. Methods According to the criteria in the Chinese guidelines for prevention and treatment of dyslipidemia in adults - 2016 version , Dyslipidemia International Study-China (DYSIS-China) database was re-analyzed. DYSIS-China database included 25 317 dyslipidemia out-patients who received at least one lipid-lowering drug for at least three months. Compliance rate of low density lipoprotein cholesterol (LDL-C) and non-HDL-C, and the gap between actual levels and target level of these patients were descriptively analyzed. Results The analysis of DYSIS-China database showed that 96.6% of out-patients with dyslipidemia were at high and very high risk, and the overall compliance rate of LDL-C was only 37.3%. The compliance rate for very high risk, high risk, moderate risk and low risk patients was 26.9%, 41.1%, 78.5% and 99.7% respectively. The compliance rate of LDL-C and non-HDL-C in Northeast China is obviously lower than that in other regions. The compliance rate for patients who visited to tertiary hospital and cardiology department was higher than non-tertiary hospital and other departments. The average difference between LDL-C actual level and target level was 39.7 mg/dl and 33.9 mg/dl in very high risk and high risk patients. 87.7% of patients received statin monotherapy. Simvastatin and atorvastatin were most commonly used. Majority of patients received moderate-intensity of simvastatin, 20-40 mg/d or equivalent statins. Conclusions The compliance rate of lipid lowering therapy in Chinese patients is still very low, especially for high risk and very high risk patients. There is a big gap between LDL-C actual level and target level. Key words: Dyslipidemias; Coronary artery disease; Lipid-lowering therapy; DYSIS-China; Statin